Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDGFRB | P09619 | 8/20 | 0.44 |
| ▸ | EGFR | P00533 | 4/20 | 0.44 |
| ▸ | AURKA | O14965 | 3/20 | 0.44 |
| ▸ | FLT3 | P36888 | 3/20 | 0.44 |
| ▸ | CSF1R | P07333 | 2/20 | 0.44 |
| ▸ | FLT4 | P35916 | 2/20 | 0.44 |
| ▸ | KDR | P35968 | 3/20 | 0.43 |
| ▸ | KIT | P10721 | 3/20 | 0.42 |
| ▸ | RAF1 | P04049 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29238336 | 0.93 | EGFR (0.44) | PDGFRBEGFRAURKAFLT3CSF1R | |
| SCHEMBL29238204 | 0.93 | EGFR (0.52) | EGFRFLT4KDRKITRAF1 | |
| SCHEMBL29238245 | 0.90 | EGFR (0.44) | PDGFRBEGFRFLT3CSF1RFLT4 | |
| SCHEMBL29238258 | 0.90 | KIT (0.47) | PDGFRBEGFRAURKAFLT3CSF1R | |
| SCHEMBL26535477 | 0.89 | EGFR (0.43) | PDGFRBEGFRFLT3CSF1RFLT4 | |
| SCHEMBL26100122 | 0.89 | RAF1 (0.47) | PDGFRBEGFRFLT3CSF1RFLT4 | |
| SCHEMBL29238266 | 0.87 | PDGFRB (0.41) | PDGFRBEGFRFLT3CSF1RFLT4 | |
| SCHEMBL31137774 | 0.86 | EGFR (0.54) | EGFRKDRRAF1 | |
| SCHEMBL30394281 | 0.84 | EGFR (0.52) | PDGFRBEGFRFLT3KDRKIT | |
| SCHEMBL26099433 | 0.84 | EGFR (0.52) | PDGFRBEGFRFLT3KDRKIT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260138959-A1 | QUINAZOLINE DERIVATIVE COMPOUND AND USE THEREOF | VORONOI INC (KR) | 2026-05-21 | — | — | US | claimed |
| EP-4424675-A1 | QUINAZOLINE DERIVATIVE COMPOUND AND USE THEREOF | Voronoi Inc. (KR) | 2024-09-04 | — | — | EP | claimed |
| CN-118201909-A | Quinazoline derivative compound and use thereof | 株式会社沃若诺伊 | 2024-06-14 | — | — | CN | claimed |
| WO-2023075529-A1 | QUINAZOLINE DERIVATIVE COMPOUND AND USE THEREOF | 보로노이바이오 주식회사 | 2023-05-04 | — | — | WO | claimed |
| US-20260138959-A1 | QUINAZOLINE DERIVATIVE COMPOUND AND USE THEREOF | VORONOI INC (KR) | 2026-05-21 | — | — | US | disclosed |
| EP-4424675-A1 | QUINAZOLINE DERIVATIVE COMPOUND AND USE THEREOF | Voronoi Inc. (KR) | 2024-09-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260138959-A1 | QUINAZOLINE DERIVATIVE COMPOUND AND USE THEREOF | PDGFRA, KIT, PDGFRB | PDGFRB 3/4885EGFR 79/4885AURKA 583/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.